Combination of IFN-α/Gm-CSF as a Maintenance Therapy for Multiple Myeloma Patients After Autologous Stem Cell Transplantation (ASCT): A Prospective Phase II Study.

"Disclosure: This manuscript has been read and approved by all authors. This paper is unique and is not under consideration by any other publication and has not been published elsewhere. The peer reviewers of this paper report no conflicts of interest. Funding for the study was provided to Dr Jan S Moreb by Immunex/Berlex, the makers of GM-CSF. The authors confirm that they have permission to reproduce any copyrighted material."

"This work was supported by Immunex and later Berlex who also provided free GM-CSF for this study. Disclosure: This manuscript has been read and approved by all authors. This paper is unique and is not under consideration by any other publication and has not been published elsewhere. The peer reviewers of this paper report no conflicts of interest. Funding for the study was provided to Dr Jan S Moreb by Immunex/Berlex, the makers of GM-CSF. The authors confirm that they have permission to reproduce any copyrighted material."